Published in J Clin Oncol on March 01, 1998
Impact of gene patents and licensing practices on access to genetic testing for inherited susceptibility to cancer: comparing breast and ovarian cancers with colon cancers. Genet Med (2010) 2.07
The role of prophylactic surgery in cancer prevention. World J Surg (2007) 1.51
Knowledge about genetic risk for breast cancer and perceptions of genetic testing in a sociodemographically diverse sample. J Behav Med (2000) 1.37
American Society of Clinical Oncology policy statement on medicaid reform. J Clin Oncol (2014) 1.16
Development and preliminary evaluation of a clinical guidance programme for the decision about prophylactic oophorectomy in women undergoing a hysterectomy. Qual Saf Health Care (2002) 1.10
The limited incorporation of economic analyses in clinical practice guidelines. J Gen Intern Med (2002) 1.10
Current knowledge on contralateral prophylactic mastectomy among women with sporadic breast cancer. Oncologist (2011) 1.07
A cost-effectiveness analysis of prophylactic surgery versus gynecologic surveillance for women from hereditary non-polyposis colorectal cancer (HNPCC) Families. Fam Cancer (2011) 1.07
Comparative effectiveness of screening and prevention strategies among BRCA1/2-affected mutation carriers. Breast Cancer Res Treat (2010) 1.07
Classification of Missense Mutations of Disease Genes. J Am Stat Assoc (2005) 0.99
Risk-reducing strategies for women carrying BRCA1/2 mutations with a focus on prophylactic surgery. BMC Womens Health (2010) 0.94
Impact of screening for breast cancer in high-risk women on health-related quality of life. Br J Cancer (2004) 0.92
A simulation model to predict the impact of prophylactic surgery and screening on the life expectancy of BRCA1 and BRCA2 mutation carriers. Cancer Epidemiol Biomarkers Prev (2012) 0.91
Peritoneal carcinoma in women with genetic susceptibility: implications for Jewish populations. Fam Cancer (2004) 0.88
Acceptance of preventive surgeries by Israeli women who had undergone BRCA testing. Fam Cancer (2006) 0.85
Cancer genetics services: a systematic review of the economic evidence and issues. Br J Cancer (2004) 0.85
Great expectations: historical perspectives on genetic breast cancer testing. Am J Public Health (1999) 0.82
A simulation model approach to analysis of the business case for eliminating health care disparities. BMC Med Res Methodol (2011) 0.81
Estimating the survival benefits gained from providing national cancer genetic services to women with a family history of breast cancer. Br J Cancer (2004) 0.78
Comparison of physicians' and cancer prone women's attitudes about breast/ovarian prophylactic surgery. Results from two national surveys. Fam Cancer (2001) 0.78
Women's views of two interventions designed to assist in the prophylactic oophorectomy decision: a qualitative pilot evaluation. Health Expect (2002) 0.75
Breast and ovarian cancer prone women and prophylactic surgery temptation. J Clin Oncol (1998) 0.75
Economic evaluation of chemoprevention of breast cancer with tamoxifen and raloxifene among high-risk women in Japan. Br J Cancer (2009) 0.75
Phase III multicenter randomized trial of the Dartmouth regimen versus dacarbazine in patients with metastatic melanoma. J Clin Oncol (1999) 5.95
Handheld cellular telephone use and risk of brain cancer. JAMA (2000) 3.59
Leptomeningeal metastases in the MRI era. Neurology (2010) 3.48
Characteristics of adult celiac disease in the USA: results of a national survey. Am J Gastroenterol (2001) 3.09
Weekly trastuzumab and paclitaxel therapy for metastatic breast cancer with analysis of efficacy by HER2 immunophenotype and gene amplification. J Clin Oncol (2001) 3.06
Epidemiologic analysis of warfare. A historical review. JAMA (1991) 2.67
Cigarette smoking and the colorectal adenoma-carcinoma sequence: a hypothesis to explain the paradox. Am J Epidemiol (1998) 2.25
Colonoscopic screening for neoplasms in asymptomatic first-degree relatives of colon cancer patients. A controlled, prospective study. Dis Colon Rectum (1992) 1.86
Risk of colorectal adenomas and advanced neoplasia in Hispanic, black and white patients undergoing screening colonoscopy. Aliment Pharmacol Ther (2012) 1.79
International Consensus Conference on High-Dose Therapy with Hematopoietic Stem Cell Transplantation in Aggressive Non-Hodgkin's Lymphomas: report of the jury. J Clin Oncol (1999) 1.76
Cost-effectiveness of vaccination against pneumococcal bacteremia among elderly people. JAMA (1997) 1.74
Response to mesna, doxorubicin, ifosfamide, and dacarbazine in 108 patients with metastatic or unresectable sarcoma and no prior chemotherapy. J Clin Oncol (1989) 1.69
Serotherapy of a patient with a monoclonal antibody directed against a human lymphoma-associated antigen. Cancer Res (1980) 1.66
Stroke in patients with cancer: incidence and etiology. Neurology (2004) 1.65
Problems with interval estimates of the incremental cost-effectiveness ratio. Med Decis Making (1999) 1.63
Immunization of metastatic breast cancer patients with a fully synthetic globo H conjugate: a phase I trial. Proc Natl Acad Sci U S A (2001) 1.63
Cost-effectiveness analysis and policy choices: investing in health systems. Bull World Health Organ (1994) 1.63
Benefits and costs of screening Ashkenazi Jewish women for BRCA1 and BRCA2. J Clin Oncol (1999) 1.57
A population-based study of the incidence of malignant small bowel tumours: SEER, 1973-1990. Int J Epidemiol (1996) 1.56
The quality of life associated with prophylactic treatments for women with BRCA1/2 mutations. Cancer J Sci Am (2000) 1.52
Factors correlated with progression-free survival after high-dose chemotherapy and hematopoietic stem cell transplantation for metastatic breast cancer. JAMA (1999) 1.49
Granulocyte-macrophage colony stimulating factor expands the circulating haemopoietic progenitor cell compartment in man. Lancet (1988) 1.43
Histology and outcomes of newly detected lung lesions in melanoma patients. Ann Oncol (2011) 1.43
Cancer screening and prevention practices of inner-city physicians. Am J Prev Med (2000) 1.40
Statistical issues in analysis of diagnostic imaging experiments with multiple observations per patient. Radiology (2001) 1.40
Clinical aspects of postirradiation sarcomas. J Natl Cancer Inst (1988) 1.39
Evaluation of Elispot assays: influence of method and operator on variability of results. J Immunol Methods (2004) 1.36
Randomized trial of black cohosh for the treatment of hot flashes among women with a history of breast cancer. J Clin Oncol (2001) 1.35
The role of cytologic evaluation of pleural fluid in the diagnosis of malignant mesothelioma. Chest (1997) 1.31
A standardization method to adjust for the effect of patient selection in phase II clinical trials. Stat Med (2001) 1.30
Variations in the use of adjuvant chemotherapy for node-positive colon cancer in the elderly: a population-based study. Cancer J (2001) 1.30
Smoking and lung cancer risk in American and Japanese men: an international case-control study. Cancer Epidemiol Biomarkers Prev (2001) 1.29
Handheld cellular telephones and risk of acoustic neuroma. Neurology (2002) 1.27
Family history of colorectal adenomatous polyps and increased risk for colorectal cancer. Ann Intern Med (1998) 1.27
Risk factors for adenocarcinomas and malignant carcinoids of the small intestine: preliminary findings. Cancer Epidemiol Biomarkers Prev (1994) 1.26
Current concepts: malignant mesothelioma. N Engl J Med (1980) 1.24
Intracellular neutralization of SV40 tumor antigens following microinjection of specific antibody. Cell (1980) 1.23
Association of melanoma and neurocutaneous melanocytosis with large congenital melanocytic naevi--results from the NYU-LCMN registry. Br J Dermatol (2005) 1.23
Knowledge, beliefs, and barriers relevant to colorectal cancer screening in an urban population: a pilot study. Fam Community Health (2001) 1.22
Microangiopathic hemolytic anemia and cancer: a review. Medicine (Baltimore) (1979) 1.21
Creutzfeldt-Jakob disease: familial clustering among Libyan-born Israelis. Neurology (1979) 1.21
Asbestos-associated diseases in a cohort of cigarette-filter workers. N Engl J Med (1989) 1.19
Mechanisms of death in the CABG Patch trial: a randomized trial of implantable cardiac defibrillator prophylaxis in patients at high risk of death after coronary artery bypass graft surgery. Circulation (1999) 1.19
Multimodality therapy for malignant mesothelioma based on a study of natural history. Am J Med (1980) 1.19
Expression of osteoprotegerin (OPG), TNF related apoptosis inducing ligand (TRAIL), and receptor activator of nuclear factor kappaB ligand (RANKL) in human breast tumours. J Clin Pathol (2006) 1.14
A role for a melanosome transport signal in accessing the MHC class II presentation pathway and in eliciting CD4+ T cell responses. J Immunol (1999) 1.12
Evaluation of CD8(+) T-cell frequencies by the Elispot assay in healthy individuals and in patients with metastatic melanoma immunized with tyrosinase peptide. Int J Cancer (2000) 1.10
Sarcomas of soft tissue and bone. Cancer (1991) 1.10
High-dose ifosfamide with mesna uroprotection: a phase I study. J Clin Oncol (1990) 1.09
Ciprofloxacin versus trimethoprim/sulfamethoxazole for prophylaxis of bacterial infections in bone marrow transplant recipients: a randomized, controlled trial. J Clin Oncol (1995) 1.09
Recurring loss involving chromosomes 1, 3, and 22 in malignant mesothelioma: possible sites of tumor suppressor genes. Genes Chromosomes Cancer (1989) 1.09
Node status has prognostic significance in the multimodality therapy of diffuse, malignant mesothelioma. J Clin Oncol (1993) 1.08
Increased expression of the cyclin D1 gene in Barrett's esophagus. Cancer Epidemiol Biomarkers Prev (1996) 1.07
Phase II trial of ifosfamide with mesna in previously treated metastatic sarcoma. Cancer Treat Rep (1985) 1.07
Early peritoneal mesothelioma: a treatable malignancy. Lancet (1985) 1.06
Predictors of survival after hepatic resection among patients with colorectal liver metastasis. Br J Cancer (2007) 1.05
Response of LNCaP spheroids after treatment with an alpha-particle emitter (213Bi)-labeled anti-prostate-specific membrane antigen antibody (J591). Cancer Res (2001) 1.04
Clinical presentation and natural history of benign and malignant mesothelioma. Semin Oncol (1981) 1.03
Molecular genetics of small bowel cancer. Cancer Epidemiol Biomarkers Prev (1997) 1.03
Quality of health information on the Internet. JAMA (2001) 1.02
Influence of health insurance, hospital factors and physician volume on receipt of immediate post-mastectomy reconstruction in women with invasive and non-invasive breast cancer. Breast Cancer Res Treat (2012) 1.02
Bayesian estimation of cost-effectiveness ratios from clinical trials. Health Econ (1999) 1.02
Radiation therapy in the management of patients with mesothelioma. Int J Radiat Oncol Biol Phys (1982) 1.01
Malignant mesothelioma following radiation exposure. J Clin Oncol (1983) 0.99
Intracerebral and subarachnoid hemorrhage in patients with cancer. Neurology (2010) 0.99
Helicobacter pylori seroprevalence and colorectal neoplasia: evidence against an association. J Natl Cancer Inst (1995) 0.99
Risk factors for a causal intermediate and an endpoint: reconciling differences. Am J Epidemiol (2000) 0.98
Risk factors for biliary tract cancers. Am J Gastroenterol (1999) 0.98
Risk of duodenal adenoma in celiac disease. Scand J Gastroenterol (2003) 0.98
Adjuvant therapy for sarcomas. Semin Oncol (1991) 0.98
Induction of antibodies against GM2 ganglioside by immunizing melanoma patients using GM2-keyhole limpet hemocyanin + QS21 vaccine: a dose-response study. Clin Cancer Res (2000) 0.98
Temporal variation in chlorinated hydrocarbons in healthy women. Cancer Epidemiol Biomarkers Prev (1997) 0.97
The impact of colonoscopy on the early detection of colonic neoplasms in patients with rectal bleeding. Ann Surg (1987) 0.96
Recurrence rates for colorectal polyps. Cancer (1985) 0.96
Peritoneal mesothelioma: natural history and response to chemotherapy. J Clin Oncol (1983) 0.96
Chromosome changes in malignant mesothelioma. Cancer Genet Cytogenet (1986) 0.96
Radiation therapy for breast cancer and increased risk for esophageal carcinoma. Ann Intern Med (1998) 0.95
Multimodality therapy in the management of angiosarcoma of the breast. Cancer (1982) 0.95
Cytoreduction with iodine-131-anti-CD33 antibodies before bone marrow transplantation for advanced myeloid leukemias. Bone Marrow Transplant (2003) 0.95
The use of agarose in the determination of anchorage-independent growth. In Vitro (1979) 0.95
A prospective study of oral lesions and their predictive value for progression of HIV disease. Oral Dis (1997) 0.95
5-year results of dose-intensive sequential adjuvant chemotherapy for women with high-risk node-positive breast cancer: A phase II study. J Clin Oncol (1999) 0.94
A course in medical research study design and analysis. J Med Educ (1987) 0.93
Multiple primary neoplasms in association with prostate cancer in black and white patients. Cancer (1987) 0.93
Response of small cell carcinoma of pancreas to a small cell lung cancer regimen: a case report. Cancer Invest (1996) 0.92
Colonic neoplasms in asymptomatic first-degree relatives of colon cancer patients. Am J Gastroenterol (1988) 0.92
Levels of p53 antigen in the plasma of patients with adenomas and carcinomas of the colon. Cancer Lett (1995) 0.92
Interactions among GSTM1, GSTT1 and GSTP1 polymorphisms, cruciferous vegetable intake and breast cancer risk. Carcinogenesis (2007) 0.90
Association of adenocarcinoma and squamous cell carcinoma of the esophagus with tobacco-related and other malignancies. Cancer Epidemiol Biomarkers Prev (1997) 0.90
Doxorubicin followed by sequential paclitaxel and cyclophosphamide versus concurrent paclitaxel and cyclophosphamide: 5-year results of a phase II randomized trial of adjuvant dose-dense chemotherapy for women with node-positive breast carcinoma. Clin Cancer Res (2001) 0.90
Malignant mesothelioma with brain metastases. Am J Med (1986) 0.90
Clinical aspects of multiple primary neoplasms. Cancer Detect Prev (1989) 0.90
Intralesional resection of primary and metastatic sarcoma involving the spine: outcome analysis of 59 patients. Neurosurgery (2001) 0.89
Decision analysis of tamoxifen for the prevention of invasive breast cancer. Cancer J (2000) 0.88
Prevention with tamoxifen or other hormones versus prophylactic surgery in BRCA1/2-positive women: a decision analysis. Cancer J Sci Am (2000) 0.88
Risk stratification for coronary bypass surgery in patients with left ventricular dysfunction: analysis of the coronary artery bypass grafting patch trial database. Circulation (1999) 0.88